Texas Biomedical Research Institute is an independent nonprofit research institute in San Antonio, Texas, founded in 1941 and operating from a single 200-acre campus with more than 360 staff.[S2] It is not a conventional contract research organization, and the difference matters for how a sponsor engages with it. Two capabilities set it apart: it holds what it describes as the only privately owned biosafety level 4 laboratory in the United States,[S3] and it hosts the Southwest National Primate Research Center, which it describes as the only National Primate Research Center with on-site access to BSL-4 containment.[S4] This profile summarizes those capabilities, how commercial sponsors can contract work, and the institute's stated compliance information.
The institute states that its biosafety level 4 laboratory is the only privately owned facility of its kind in the United States.[S3] BSL-4 containment is required for work with agents such as filoviruses for which there is no available vaccine or therapy, and very few sites worldwide can host it. The Southwest National Primate Research Center is one of the National Primate Research Centers and holds more than 2,500 non-human primates; the institute describes it as the only such center with on-site access to BSL-4 containment.[S4] For a sponsor developing a medical countermeasure that requires non-human primate studies under high containment, the combination of the two on one campus is the practical reason to approach this institute rather than a commercial CRO.
Two routes are described. The Applied Science and Innovation group handles fee-for-service work, contract research and licensing for commercial partners.[S5] Separately, work involving the primate center is requested through the center's own application process.[S4] Because the institute is a nonprofit whose primary business is its own research programs, sponsors should expect the engagement model, timelines and intellectual property terms to differ from those of a commercial CRO, and should raise those points early.
The institute states AAALAC accreditation held since 1973, annual inspection by the US Department of Agriculture Animal and Plant Health Inspection Service, an Institutional Animal Care and Use Committee, and adherence to Public Health Service policy.[S6] One wording point: that page names the Office for Human Research Protections rather than the Office of Laboratory Animal Welfare in connection with the PHS policy. OHRP oversees human subjects research; the office responsible for laboratory animal welfare assurances is OLAW.[R5] The statement is quoted as published, and the discrepancy is noted rather than corrected silently. AAALAC International accreditation is a voluntary evaluation of an institution's animal care and use program, re-evaluated every three years,[R3] and USDA registration and an OLAW Animal Welfare Assurance relate to the Animal Welfare Act and the PHS Policy respectively;[R4][R5] none of these establishes GLP compliance, which applies to individual studies.[R2] FDA does not approve or certify laboratories; registration with FDA does not denote approval.[R6] This profile does not evaluate the institute's animal care program; the statements above are its own.
GLP. A defense-related press release from July 2026 refers to GLP and FDA-facing work.[S7] No GLP statement was found on the service pages themselves, so a sponsor needing a GLP study should confirm the scope, the governing regulation and the quality assurance arrangements directly.[R2]
| Name | Texas Biomedical Research Institute[S1] |
|---|---|
| Location | San Antonio, Texas, United States; a single campus of about 200 acres[S2] |
| Founded | 1941[S2] |
| Ownership | Independent nonprofit research institute[S2] |
| Staff | More than 360[S2] |
| Containment | Described as the only privately owned BSL-4 laboratory in the United States[S3] |
| Primate center | Southwest National Primate Research Center, holding more than 2,500 non-human primates; described as the only National Primate Research Center with on-site BSL-4 access[S4] |
| Routes for sponsors | Applied Science and Innovation for fee-for-service, contract research and licensing; the primate center's own application process for SNPRC work[S4][S5] |
| Animal welfare | AAALAC accredited since 1973; annual USDA APHIS inspection; IACUC; adherence to PHS policy (the page names OHRP rather than OLAW)[S6] |
| GLP | Referred to in a July 2026 defense-related press release; not found on the service pages[S7] |
| Revenue | Not published |
| Website | www.txbiomed.org |
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.